<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02309307</url>
  </required_header>
  <id_info>
    <org_study_id>CP-STR-01</org_study_id>
    <nct_id>NCT02309307</nct_id>
  </id_info>
  <brief_title>Tissue Repair Device (VergenixTM STR) in Patients With Epicondylitis (Tennis Elbow)</brief_title>
  <acronym>CP-STR-01</acronym>
  <official_title>A Prospective, Open Label, Single Arm, Multi-center Study to Assess the Safety and Performance of a Soft Tissue Repair Device (VergenixTM STR) in Patients With Epicondylitis (Tennis Elbow)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Collplant</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Collplant</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The VergenixTM STR device is intended for the repair of non ruptured tendon injuries&#xD;
      (Tendinopathy).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The VergenixTM STR device is an advanced Soft tissue repair device, made of lyophilized Type&#xD;
      I rhCollagen and Calcium Chloride that will be mixed with autologous PRP prior to injection&#xD;
      for the repair of non ruptured tendon injuries (Tendinopathy). Three (3) ml of the mixed&#xD;
      solution will be injected into the common extensor tendon.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2015</start_date>
  <completion_date type="Actual">August 24, 2016</completion_date>
  <primary_completion_date type="Actual">August 24, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in pain as a continuous outcome measure using the Patient-Rated Tennis Elbow Evaluation (PRTEE) questionnaire.</measure>
    <time_frame>Up to 194 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Disability using the PRTEE questionnaire.</measure>
    <time_frame>Up to 194 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tendon thickness (i.e tendon healing/improvement) and Doppler activity using US at 3M.</measure>
    <time_frame>Up to 194 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Health related Quality of life parameters questionnaire.</measure>
    <time_frame>Up to 194 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain free/maximum grip strength (Dynamometer)</measure>
    <time_frame>Up to 194 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Non Ruptured Tendon Injuries</condition>
  <condition>Tendinopathy</condition>
  <arm_group>
    <arm_group_label>Arm 1 Tissue Repair Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tissue Repair Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tissue Repair Device (VergenixTM STR)</intervention_name>
    <description>Administration of Soft Tissue Repair Device</description>
    <arm_group_label>Arm 1 Tissue Repair Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Man or woman aged 18 - 80 years old.&#xD;
&#xD;
          2. Clinical diagnosis of lateral epicondylitis based on site of pain, pain&#xD;
&#xD;
             elicited with active extension of the wrist in pronation and elbow&#xD;
&#xD;
             extension.&#xD;
&#xD;
          3. Documented ultrasonography diagnosis of common extensor&#xD;
&#xD;
             tendinosis and possible tear based on abnormal echotexture (tendon&#xD;
&#xD;
             thickening, anechoic areas, areas of hypoechogencicity, loss of&#xD;
&#xD;
             fibrillar pattern).&#xD;
&#xD;
          4. Chronic symptoms (equal or greater than 3 months).&#xD;
&#xD;
          5. PRTEE questionnaire score of at least 50 out of 100.&#xD;
&#xD;
          6. For child-bearing potential females, documentation of birth&#xD;
&#xD;
             control.&#xD;
&#xD;
          7. Signing informed consent form. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute symptom onset (less than 3 months).&#xD;
&#xD;
          2. History of acute elbow trauma.&#xD;
&#xD;
          3. History of Rheumatoid Arthritis.&#xD;
&#xD;
          4. History of Inflammatory disease&#xD;
&#xD;
          5. History of Fibromyalgia&#xD;
&#xD;
          6. The patient has active malignant disease of any kind. A patient who&#xD;
&#xD;
             has had a malignant disease in the past, was treated and is currently&#xD;
&#xD;
             disease-free for at least 5 years, may be considered for study entry.&#xD;
&#xD;
          7. The patient is treated with anti-coagulant medication&#xD;
&#xD;
          8. The patient previously underwent a surgery for lateral&#xD;
&#xD;
             epicondylitis.&#xD;
&#xD;
          9. The patient previously received local injections, including steroids&#xD;
&#xD;
             within the last 30 days&#xD;
&#xD;
         10. Signs of other causes for lateral elbow pain (posterior interosseous&#xD;
&#xD;
             nerve entrapment, osteochondral lesion).&#xD;
&#xD;
         11. Wounds around the elbow&#xD;
&#xD;
         12. Likely problems, in the judgment of the investigator, with maintaining follow-up.&#xD;
&#xD;
         13. Clinically significant abnormalities in hematology and blood&#xD;
&#xD;
             chemistry lab tests at screening that in the opinion of the&#xD;
&#xD;
             investigator might interfere with the patient's safety or participation&#xD;
&#xD;
             in the study.&#xD;
&#xD;
         14. Known as positive HIV, hepatitis B, or hepatitis C.&#xD;
&#xD;
         15. Known history of a significant medical disorder, which in the&#xD;
&#xD;
             investigator's judgment contraindicates the patient's participation.&#xD;
&#xD;
         16. Known hypersensitivity and/or allergy to collagen.&#xD;
&#xD;
         17. Drug or alcohol abuse (by history).&#xD;
&#xD;
         18. Pregnancy of child-bearing potential females.&#xD;
&#xD;
         19. Participation in another study within 30 days prior to screening&#xD;
&#xD;
        visit.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hadassah MC</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir MC</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh MC</name>
      <address>
        <city>Zrifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>December 3, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety and performance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
    <mesh_term>Tennis Elbow</mesh_term>
    <mesh_term>Tendon Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

